Gwen A. Melincoff

Insider Reports History

Entity
Individual
Location
C/O Tobira Therapeutics, Inc., 701 Gateway Boulevard, South San Francisco, California
Signature
/s/ Daniel Porco, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Gwen A. Melincoff:

Stock Role Class Num Shares Value Price $ Report Date Ownership
COLLEGIUM PHARMACEUTICAL, INC Director Common Stock 52.5 K $1.69 M $32.30 May 16, 2024 Direct
Gain Therapeutics, Inc. Director Stock Option (right to buy) 15 K $87.9 K $5.86 Jun 24, 2024 Direct
SOLENO THERAPEUTICS INC Director Common Stock 666 $24.3 K $36.49 Aug 26, 2022 Direct
Protalix BioTherapeutics, Inc. Director Stock Options (Right to Buy) 61.7 K Sep 29, 2023 Direct
SOLENO THERAPEUTICS INC Director Stock option (right to buy) 10 K May 26, 2023 Direct

Insider Reports Filed by Gwen A. Melincoff

Symbol Company Period Transactions Value $ Form Type Date Filed Role
GANX Gain Therapeutics, Inc. Jun 24, 2024 1 $0 4 Jun 26, 2024 Director
COLL COLLEGIUM PHARMACEUTICAL, INC May 16, 2024 1 $0 4 May 16, 2024 Director
PLX Protalix BioTherapeutics, Inc. Sep 29, 2023 1 $0 4 Oct 3, 2023 Director
GANX Gain Therapeutics, Inc. Jun 23, 2023 1 $0 4 Jun 26, 2023 Director
SLNO SOLENO THERAPEUTICS INC May 25, 2023 2 $0 4 May 26, 2023 Director
COLL COLLEGIUM PHARMACEUTICAL, INC May 18, 2023 1 $0 4 May 19, 2023 Director
GANX Gain Therapeutics, Inc. Sep 20, 2022 1 $0 4 Sep 22, 2022 Director
PLX Protalix BioTherapeutics, Inc. Sep 7, 2022 1 $0 4 Sep 9, 2022 Director
SLNO SOLENO THERAPEUTICS INC Aug 26, 2022 0 $0 4 Oct 14, 2022 Director
SLNO SOLENO THERAPEUTICS INC Jun 1, 2022 1 $0 4 Oct 14, 2022 Director
COLL COLLEGIUM PHARMACEUTICAL, INC May 19, 2022 1 $0 4 May 23, 2022 Director
SLNO SOLENO THERAPEUTICS INC Jun 1, 2021 1 $0 4 Jun 4, 2021 Director
COLL COLLEGIUM PHARMACEUTICAL, INC May 20, 2021 1 $0 4 May 24, 2021 Director